Dimerix Ltd has released a press release.
Dimerix Confirms Phase 3 FSGS Study Design With EMA
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Dimerix
- DMX-200 Remains Eligible for Accelerated Approval
- COVID-19 Study Recruits Multiple Patients in Europe
- Major Shareholder Loan for $5 Million
- Clinical Study in Patients with COVID-19 Progresses
- DMX-200 Competitive Position Further Enhanced
Later from Dimerix
- Dimerix Receives Innovation Passport and ILAP Designation
- FDA Confirms Phase 3 Study Design in FSGS Kidney Disease
- DMX-200 COVID-19 Study Opens More Sites in Europe and UK
- Successful $20m Placement to Fund Phase 3 Trials
- Response to ASX Query
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix